Charles River Laboratories International logo
Charles River Laboratories International CRL
$ 192.57 -0.96%

Quarterly report 2025-Q3
added 11-05-2025

report update icon

Charles River Laboratories International Financial Statements 2011-2025 | CRL

Annual Financial Statements Charles River Laboratories International

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

8.54 B 12.5 B 11 B 14.6 B 14.2 B 7.68 B 5.81 B 5.22 B 3.68 B 3.61 B 3.36 B 2.77 B 2.05 B 1.7 B

Shares

51.4 M 51.2 M 50.8 M 50.3 M 49.6 M 49.7 M 49 M 48.6 M 47 M 47.6 M 47.6 M 48.5 M 48.4 M 50.8 M

Historical Prices

166 244 217 291 286 156 142 107 87 73.4 76.7 59.4 40.7 35.1

Net Income

22.2 M 475 M 486 M 391 M 364 M 252 M 226 M 123 M 155 M 149 M 127 M 103 M 97.3 M 110 M

Revenue

4.05 B 4.13 B 3.98 B 3.54 B 2.92 B 2.62 B 2.27 B 1.86 B 1.68 B 1.36 B 1.3 B 1.17 B 1.13 B 1.14 B

Gross Profit

- - - - - 958 M 840 M 701 M 647 M 532 M 476 M 401 M 397 M 402 M

Operating Income

227 M 617 M 651 M 590 M 433 M 351 M 331 M 288 M 238 M 206 M 178 M 151 M 166 M 174 M

Interest Expense

-16.5 M 95.5 M 30.5 M 73.9 M 86.4 M 60.9 M 63.8 M 29.8 M 27.7 M 15.1 M 12 M 21 M 33.3 M 42.6 M

EBITDA

589 M 931 M 955 M 855 M 668 M 549 M 493 M 419 M 279 M 301 M 274 M 248 M 247 M 204 M

Operating Expenses

- - - - - 607 M 509 M 413 M 409 M 325 M 298 M 249 M 231 M 220 M

General and Administrative Expenses

751 M 748 M 665 M 620 M 529 M 486 M 420 M 365 M 368 M 283 M 264 M 224 M 207 M 199 M

All numbers in USD currency

Quarterly Income Statement Charles River Laboratories International

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

49.2 M 49.1 M 50.7 M 51.1 M 51.4 M 51.6 M 51.4 M 51.3 M 51.3 M 51.2 M 51.1 M 50.9 M 50.9 M 50.8 M 50.6 M 50.5 M 50.4 M 50.3 M 50 M 49.8 M 49.7 M 49.6 M 49.2 M 48.9 M 48.8 M 48.8 M 48.5 M 48.2 M 48.3 M 48.2 M 47.8 M 47.4 M 47.5 M 47.6 M 47.5 M 47.4 M 47.2 M 47.1 M 46.6 M 46.7 M 46.3 M 46.7 M 46.8 M 47.3 M 46 M 46.9 M 47.1 M 47.6 M 47.9 M 48.3 M 47.7 M 48.9 B 47.6 M 48 M 48.3 M 48.9 M 50.1 M 51 M 53.9 M

Net Income

54.4 M 52.3 M 25.5 M - 69.7 M 94.1 M 73 M - 87.4 M 97 M 103 M - 96.5 M 109 M 93 M - 103 M 88.4 M 61.5 M 143 M 103 M 67.4 M 50.8 M 80.3 M 72.8 M 43.7 M 55.1 M 59.7 M 60.4 M 53.7 M 52.6 M -29.8 M 52.5 M 54 M 46.8 M 44.7 M 37.7 M 35.2 M 37.1 M 31.9 M 37.4 M 48.5 M 31.5 M 27.2 M 32.4 M 35.8 M 32.4 M 19.1 M 31.2 M 27.7 M 25.8 M - 22.2 M 30.6 M 26.5 M - 18.9 M 32.3 M 31.3 M

Revenue

1 B 1.03 B 984 M - 1.01 B 1.03 B 1.01 B - 1.03 B 1.06 B 1.03 B - 989 M 973 M 914 M - 896 M 915 M 825 M 791 M 743 M 683 M 707 M 691 M 668 M 658 M 605 M 602 M 585 M 585 M 494 M 478 M 464 M 469 M 446 M 467 M 426 M 434 M 355 M 354 M 349 M 340 M 320 M 330 M 328 M 341 M 299 M 289 M 292 M 293 M 291 M - 279 M 285 M 286 M - 278 M 288 M 286 M

Cost of Revenue

- - - - 661 M 672 M - - 665 M 661 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - 300 M 289 M 232 M 252 M 262 M 246 M 238 M 212 M 226 M 216 M 216 M 181 M 167 M 177 M 185 M 171 M 180 M 156 M 170 M 141 M 141 M 138 M 133 M 120 M 120 M 118 M 126 M 109 M 88.2 M 99.9 M 103 M 104 M - - - - - - - -

Operating Income

134 M 100 M 74.7 M - 117 M 152 M 126 M - 152 M 165 M 168 M - 151 M 187 M 149 M - 156 M 138 M 124 M 129 M 133 M 76.8 M 94.3 M 109 M 92.8 M 79.8 M 69.8 M 102 M 84.4 M 76.7 M 67.8 M 62.8 M 74.1 M 81.7 M 69.7 M 69.1 M 58.8 M 58.1 M 51.5 M 52.3 M 55.4 M 55.7 M 43 M 40.8 M 46.2 M 51 M 39.7 M 24.6 M 40.8 M 43.2 M 42.8 M - 37.7 M 49.3 M 43.7 M - 37.1 M 53.3 M 42.3 M

Interest Expense

-22.6 M 154 K -12.2 M - 2.59 M -2.24 M 5.83 M - -6.26 M -2.66 M 34.4 M - 11.4 M 3.7 M 9.43 M - 16.5 M 16.2 M 29.7 M - 18.9 M 19.4 M 15.1 M - 5.7 M 20.8 M 9.99 M - 17.2 M 18.6 M 11.2 M - 7.67 M 7.4 M 6.98 M - 7.08 M 8.91 M 4.21 M - 3.85 M 4.38 M 3.02 M - 3 M 3.37 M 2.8 M - 2.32 M 7.54 M 8.28 M - 8.52 M 8.08 M 8.44 M - 11.9 M 10.7 M 10 M

EBITDA

219 M 220 M 195 M - 206 M 238 M 211 M - 230 M 243 M 245 M - 226 M 264 M 224 M - 224 M 206 M 185 M 129 M 192 M 134 M 152 M 109 M 145 M 129 M 115 M 102 M 128 M 120 M 101 M 62.8 M 108 M 113 M 102 M 69.1 M 92.9 M 90.4 M 76.1 M 52.3 M 79.3 M 78.9 M 65.4 M 40.8 M 72.2 M 75.3 M 59.8 M 24.6 M 108 M 83.6 M 62.8 M - 98.3 M 89.3 M 63.7 M - 101 M 96.4 M 63.5 M

General and Administrative Expenses

178 M 192 M 178 M - 199 M 170 M 186 M - 176 M 200 M 175 M - 184 M 132 M 150 M - 149 M 172 M 156 M - 128 M 128 M 130 M - 130 M 136 M 123 M - 113 M 121 M 103 M - 92.4 M 93.8 M 90.9 M - 85.6 M 100 M 82.9 M - 76.2 M 71.3 M 71.4 M - 64.5 M 67.8 M 64.8 M - 54.9 M 54.9 M 57.2 M - 51 M 49.9 M 56 M - 50.3 M 47.2 M 55 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Charles River Laboratories International CRL
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Charles River Laboratories International plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Castle Biosciences Castle Biosciences
CSTL
$ 38.85 2.32 % $ 1.08 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 16.36 -4.05 % $ 176 M chinaChina
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 17.05 -2.15 % $ 99.4 M israelIsrael
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 227.08 -2.28 % $ 166 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
$ 101.58 0.21 % $ 18.8 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 27.13 0.26 % $ 820 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.63 -2.11 % $ 2.07 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
DexCom DexCom
DXCM
$ 66.91 -2.94 % $ 25.8 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 11.92 -6.58 % $ 338 M israelIsrael
Illumina Illumina
ILMN
$ 134.29 -1.58 % $ 21.4 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 221.54 -1.96 % $ 40.2 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 66.11 4.76 % $ 4.57 B usaUSA
Guardant Health Guardant Health
GH
$ 102.09 0.7 % $ 12.5 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 20.44 3.23 % $ 1.1 B usaUSA
Celcuity Celcuity
CELC
$ 105.26 4.46 % $ 4.15 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.59 -25.21 % $ 115 K usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 0.34 -2.96 % $ 9.98 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 7.26 -0.62 % $ 658 M usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 6.86 -2.63 % $ 1.49 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 17.81 2.24 % $ 437 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 263.51 -0.46 % $ 22.1 B usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 2.13 -1.61 % $ 540 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.6 -1.52 % $ 20 B niderlandNiderland
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 28.79 -2.93 % $ 1.21 B usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
RadNet RadNet
RDNT
$ 75.0 -4.65 % $ 5.48 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 182.21 0.35 % $ 20.2 B usaUSA
Biodesix Biodesix
BDSX
$ 7.94 -1.0 % $ 1.03 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 186.28 -1.92 % $ 15.4 B irlandaIrlanda